References
- Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: twenty-fourth informational supplement M100-S24. Wayne, PA: CLSI; 2014
- Turkish Ministry of Health. Turkish Health Statistics Yearbook 2014. http://ekutuphane.sagem.gov.tr/kitaplar/saglik_istatistikleri_yilligi_2014.pdf
- Varon E, Cohen R, Béchet S, Doit C, Levy C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine 2015; 17; 33(46):6178-6185; PMID:26476365; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2015.10.015
- Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, Levine OS, Whitney CG, O'Brien KL, Moore MR, et al. Serotype Replacement Study Group. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med 2013; 10(9):e1001517; PMID:24086113; https://doi.org/http://dx.doi.org/10.1371/journal.pmed.1001517
- Tin Tin Htar M, Madhava H, Balmer P, Christopoulou D, Menegas D, Bonnet E. A review of the impact of pneumococcal polysaccharide conjugate vaccine (7-valent) on pneumococcal meningitis. Adv Ther 2013; 30(8):748-762; PMID:24000099; https://doi.org/http://dx.doi.org/10.1007/s12325-013-0051-2
- Ceyhan M, Gurler N, Yaman A, Ozturk C, Oksuz L, Ozkan S, Keser M, Salman N, Alhan E, Esel D, et al. Serotypes of Streptococcus pneumoniae isolates from children with invasive pneumococcal disease in Turkey: baseline evaluation of the introduction of the pneumococcal conjugate vaccine nationwide. Clin Vaccine Immunol 2011; 18(6):1028-1030; PMID:21508171; https://doi.org/http://dx.doi.org/10.1128/CVI.00526-10
- Ceyhan M, Ozsurekci Y, Gürler N, Öksüz L, Aydemir S, Ozkan S, Yuksekkaya S, Keser Emiroglu M, Gültekin M, et al. Serotype distribution of Streptococcus pneumoniae in children with invasive diseases in Turkey: 2008–2014. Hum Vaccin Immunother 2016; 12(2):308-313; PMID:26325175; https://doi.org/http://dx.doi.org/10.1080/21645515.2015.1078952
- Park SY, Van Beneden CA, Pilishvili T, Martin M, Facklam RR, Whitney CG. Active Bacterial Core surveillance team. Invasive pneumococcal infections among vaccinated children in the United States. Pediatr 2010; 156(3):478-483.e2; https://doi.org/http://dx.doi.org/10.1016/j.jpeds.2009.10.008
- Godot C, Levy C, Varon E, Picard C, Madhi F, Cohen R. Pneumococcal meningitis vaccine breakthroughs and failures after routine 7-valent and 13-valent pneumococcal conjugate vaccination in children in France. Pediatr Infect Dis J 2015; 34(10):e260-e263; PMID:26181894; https://doi.org/http://dx.doi.org/10.1097/INF.0000000000000818
- Navarro Torné A, Dias JG, Quinten C, Hruba F, Busana MC, Lopalco PL, Gauci AJ, Pastore-Celentano L. ECDC country experts for pneumococcal disease. European enhanced surveillance of invasive pneumococcal disease in 2010: data from 26 European countries in the post-heptavalent conjugate vaccine era. Vaccine 2014; 17; 32(29):3644-3650; https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2014.04.066
- Jones RN, Sader HS, Mendes RE, Flamm RK. Update on antimicrobial susceptibility trends among Streptococcus pneumoniae in the United States: report of ceftaroline activity from the SENTRY Antimicrobial Surveillance Program (1998–2011). Diagn Microbiol Infect Dis 2013; 75(1):107-109; PMID:23009730; https://doi.org/http://dx.doi.org/10.1016/j.diagmicrobio.2012.08.024